The predictive power of plasma proteomic profiles for future dementia onset in adults without dementia.
European Commission rejects Ipsen’s ultra-rare disease drug after two negative opinions from EMA
The European Commission has rejected Ipsen’s potential new drug palovarotene for those with the ultra-rare genetic connective tissue disorder known as fibrodysplasia ossificans progressiva, or
July 20, 2023